Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.
Alex Chehrazi‐Raffle(City of Hope), Toni K. Choueiri(Harvard University), Pedro C. Barata(University Hospitals Seidman Cancer Center), Javier Molina Cerrillomd(Hospital Universitario Ramón y Cajal), Claudia Lebedinsky(European Institute of Oncology), Benjamin Garmezy(Sarah Cannon), Rana R. McKay(University of California San Diego), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Bradley A. McGregor(Harvard University), Edgar Braendle(AVEO Oncology (United States)), Roberto Iacovelli(Agostino Gemelli University Polyclinic), Laurence Albigès(Université Paris-Saclay), Bo Jin(Jilin University), Hans J. Hammers(Southwestern Medical Center), Daniel Yick Chin Heng(University of Calgary), Sheik Emambux(Centre Hospitalier Universitaire de Poitiers), Katy Beckermann(Vanderbilt University Medical Center), Philippe Barthélémy(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k